Transbronchial needle aspiration sites and needle passes
| Both methods | G-ROSE | P-ROSE | |
| All procedures | 126 (100) | 63 (50) | 63 (50) |
| Sites aspirated | 218 (100) | 108 (50) | 110 (50) |
| Lymph node | 121 (56) | 58 (54) | 63 (57) |
| Other | 97 (44) | 50 (46) | 47 (43) |
| Needle passes | 827 (100) | 401 (48) | 426 (52) |
| Lymph node | 483 (58) | 229 (57) | 254 (60) |
| Other | 344 (42) | 172 (43) | 172 (40) |
| Diagnostic procedures | 92 (73) | 43 (47) | 49 (53) |
| Neoplastic | 82 (89) | 38 (88) | 44 (90) |
| Non-neoplastic | 10 (11) | 5 (12) | 5 (10) |
| Sites aspirated | 157 (100) | 73 (46) | 84 (54) |
| Lymph node | 109 (69) | 39 (53) | 46 (55) |
| Other | 48 (31) | 34 (47) | 38 (45) |
| Needle passes | 574 (100) | 261 (45) | 313 (55) |
| Lymph node | 326 (57) | 146 (56) | 180 (58) |
| Other | 248 (43) | 115 (44) | 133 (42) |
Data are presented as n (%). G-ROSE: Wright–Giemsa-based rapid on-site evaluation; P-ROSE: Papanicolaou-based rapid on-site evaluation.